Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Targeting TKI-resistant CML with LY3009120 and asciminib

Michael Deininger • 12 Dec 2021
ASH 2021
Chronic Myeloid Leukemia Leukemia Asciminib LY3009120 Ponatinib

Michael Deininger, MD, PhD, University of Utah, Salt Lake City, UT, describes the development of LY3009120 for patients with chronic myeloid leukemia (CML) resistant to tyrosine kinase inhibitors (TKIs) via BCR-ABL1 mutations. Ponatinib and asciminib is a potential regimen to resensitize patients to TKIs but is not feasible due to the high toxicity of the required ponatinib dose. LY3009120 was identified as a candidate molecule that when paired with asciminib, can target BCR-ABL1 mutations. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Michael Deininger

1:24
Ongoing studies in CML: investigating asciminib toxicity and improving TFR rates
Michael Deininger • 21 Oct 2022
1:09
Tolerability of bosutinib vs asciminib in heavily pre-treated patients with CML
Michael Deininger • 21 Oct 2022
1:33
ESH CML workshop highlights: 3D genomics and nuclear organization
Michael Deininger • 21 Oct 2022
1:10
Final results of the BFORE trial: bosutinib vs imatinib in CP-CML
Michael Deininger • 21 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals